Lipoprotein-X

Lipoprotein-X (Lp-X) is an abnormal low density lipoprotein found in cholestasis.

Structure

Lipoprotein-X is a lamellar particle of 30 to 70 nm in diameter as revealed by electron microscopy. It is characterized by its high content of phospholipids (66% by weight) and unesterified cholesterol (22%), and its low content of protein (6%), cholesterol esters (3%), and triglycerides (3%). The protein component is dominated by albumin, located in the core, and by apolipoprotein C, located on the surface of the particle. Using zonal ultracentrifugation, lipoprotein-X can be divided into three distinct populations: Lp-X1, Lp-X2, and Lp-X3, differing in density and apolipoprotein composition.

Pathogenesis

The pathogenesis of lipoprotein-X in cholestasis is not totally resolved. Normally, the liver excretes lipoprotein complexes into the bile showing phospholipid and unesterified cholesterol concentrations similar to Lipoprotein-X. The in vitro incubation of these bile lipoproteins with serum or albumin leads to the appearance of Lp-X–like particles. These findings suggest that the reflux of bile into the plasma compartment causes the formation of lipoprotein-X in cholestasis as a result of a physicochemical, nonmetabolic process. On the other hand, lipoprotein-X particles found in familial LCAT deficiency are identical to those in cholestasis regarding ultrastructure and biochemical composition. It has been supposed that reduced LCAT activities, common in patients with hepatocellular disease, cause, alone or in combination with other factors, the formation of Lipoprotein-X in cholestasis. Lipoprotein-X is mainly removed by the reticuloendothelial system of the liver and the spleen, as shown by studies using radioactively labeled lipoprotein-X in rats. Other organs, such as the kidney, also actively clear Lipoprotein-X from the plasma.

Literature
  • Seidel D, Alaupovic P, Furman RH (July 1969). "A lipoprotein characterizing obstructive jaundice. I. Method for quantitative separation and identification of lipoproteins in jaundiced subjects". J. Clin. Invest. 48 (7): 1211–23. doi:10.1172/JCI106085. PMC 322342. PMID 4978447.
  • Seidel D, Alaupovic P, Furman RH, McConathy WJ (December 1970). "A lipoprotein characterizing obstructive jaundice. II. Isolation and partial characterization of the protein moieties of low density lipoproteins". J. Clin. Invest. 49 (12): 2396–407. doi:10.1172/JCI106459. PMC 322741. PMID 5480863.
  • Sörös P, Böttcher J, Maschek H, Selberg O, Müller MJ (November 1998). "Lipoprotein-X in patients with cirrhosis: its relationship to cholestasis and hypercholesterolemia". Hepatology. 28 (5): 1199–205. doi:10.1002/hep.510280506. PMID 9794902.
gollark: It has metatypes to arbitrary depth, see.
gollark: We added generics. Then generic generics. Then higher-kinded types. Then higher-typed kinds.
gollark: You sound just like those who deny the amazing benefits of Macron 2.
gollark: It is; the `;` macro, ever since Macron 4 even, tells the Macron compiler to generate an anonymous trait with the previous expression as its only associated function/value.
gollark: My favourite Macron feature is the `;` macro personally.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.